Dublin-based Drug development firm ICON recorded record net new business of over $500m (€454m) during the second quarter.
That included ICON's acquisition of ClinicalRM, which has extended ICON’s presence in the market for government-funded research and has enhanced ICON’s capabilities in vaccines and infectious disease.
At the height of the Ebola crisis, ClinicalRM worked on several clinical trials in West Africa and the company is currently supporting the Zika Emergency Response plan.
Meanwhile, ICON renewed its service agreement with Pfizer, where ICON will continue to provide expertise in the planning, execution and management of Pfizer’s clinical trials.
ICON first entered into a strategic partnership with Pfizer in 2011.
Revenue for the three months to the end of June grew 5.7% year-on-year to $410.6m (€373m), while for the first half of the year revenue was 4.4% higher than the same period in 2015.
ICON currently operates from 89 locations in 37 countries and has around 12,300 employees.
In Ireland ICON employs over 1,000 staff at its global HQ in Leopardstown and in its Limerick office.